The global COVID-19 (coronavirus disease 2019) pandemic that began in late 2019 has caused more than 535 million infections and 6 million deaths as of June 2022\(^1\). Although the number of newly confirmed cases has been fallen below as 10,000 per day in South Korea, those who have been infected and survived experience long-lasting medical consequences. Those post-infection symptoms were defined as post-acute infection syndrome (PAIS) or post-acute sequelae of COVID-19 (PASC) in the literature\(^2,3\), and the number of scientific publications dealing with PAIS and PASC has been dramatically increasing since 2020.

Frequently reported residual effects from SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) include fatigue, dyspnea, chest pain, persistent loss of taste and/or smell, cognitive changes, arthralgias, and decreased quality of life\(^4,5\). With a variety of clinical presentations and degrees of severity in patients, it is necessary for oral and maxillofacial surgeons to understand the emergent effects of PAIS and PASC. In fact, PAIS after viral infections such as Dengue, Ebola, and EBV (Epstein-Barr virus) has been identified long time ago, and all kinds of non-viral infections, including bacteria and parasites, have been implicated in PAIS pathogenesis\(^6\). Unfortunately, the association between acute infectious diseases and unexplained disability remains understudied, which leads to poor recognition of these conditions in clinical practice\(^2\). Besides, as the pandemic emerged in 2019, most studies have been limited in the duration of observation\(^7\). As a result, patients might experience delayed or a complete lack of clinical care in case of PAIS. Therefore, particular attention on the pathogenesis or the treatment needs for PAIS and PASC has been made very recently by medical scientists and clinicians\(^2,3\).

Importantly, PAIS after COVID-19 is not only associated with the systemic, respiratory, and neurological symptoms, but also related to pathology in the oral and maxillofacial region. During the second wave of the COVID-19 pandemic, a sudden and rapid rise in rhino-orbital-cerebral mucormycosis incidence was observed and has been identified as a deadly complication of this viral infection\(^8\). Because of the sudden, rocket high incidence in a brief period, it was defined as COVID-19 associated mucormycosis (CAM) especially affecting maxilla and adjacent facial tissues\(^8-10\). Before the outbreak of the COVID-19 pandemic, global prevalence of mucormycosis was as low as 0.005 to 1.7 per million population\(^11\); however, the prevalence is 80 times higher than that recorded in developed countries after COVID-19\(^12\). Pathogenesis of CAM is currently understood as an opportunistic fungal infection where the immune cells in the SARS-CoV-2 infected host defense differently against commensal or invaded fungal colony\(^13\). Interestingly, other kinds of opportunistic infections have been reported in the oral and maxillofacial region as PAIS, such as worsened periodontitis, avascular necrosis of jaw, and various spectrum of oral mucositis\(^8-19\). (Table 1) One of the suggested mechanisms of those oral and maxillofacial manifestations is the direct vulnerability of the oral mucosa to SARS-CoV-2 infection. These are reported to be a consequence of the high ACE-2 expression in the epithelial cells of the oral mucosa\(^15,19\); however, further study with larger number of clinical cases is required to fully support the hypothesis.
Nonetheless, the overlap of symptoms, signs, and general features of the individual PAIS and the related oral and maxillofacial pathologies suggest the involvement of shared pathological pathways and the possibility that common diagnostic markers might be established. In addition to basic biomedical and dental research, more needs to be done to refine diagnostic criteria and obtain more reliable estimates of the PAIS prevalence. Moreover, the oral and maxillofacial surgeons need to call for unified nomenclature and better conceptualization of PAIS in the maxillofacial region, leading to the increased scientific publications in this field.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

References

1. World Health Organization (WHO). WHO coronavirus (COVID-19) dashboard [Internet]. Geneva: WHO [cited 2022 Jun 1]. Available from: https://covid19.who.int/.
2. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-infection syndromes. Nat Med 2022;28:911-23. https://doi.org/10.1038/s41591-022-01810-6
3. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and Long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 2021;4:e2128568. https://doi.org/10.1001/jamanetworkopen.2021.28568
4. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-Month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220-32. https://doi.org/10.1016/S0140-6736(20)32656-8
5. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med 2021;18:e1003773. https://doi.org/10.1371/journal.pmed.1003773
6. Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, et al.; Dubbo Infection Outcomes Study Group. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 2006;333:575. https://doi.org/10.1136/bmj.38933.585764.AE
7. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021;385:1474-84. https://doi.org/10.1056/NEJMoa2109072
8. Balushi AA, Ajmi AA, Sinani QA, Menon V, Berieki ZA, Shezawi AA, et al. COVID-19-associated mucormycosis: an opportunistic fungal infection. A case series and review. Int J Infect Dis 2022;121:203-10. https://doi.org/10.1016/j.ijid.2022.05.005
9. Ali IE, Chugh A, Cheewin T, Hattori M, Sumita YI. The rising challenge of mucormycosis for maxillofacial prosthodontists in the Covid-19 pandemic: a literature review. J Prosthodont Res 2022. https://doi.org/10.2186/jpr.JPR_D_21_00264 [Epub ahead of print]
10. Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coronavirus disease (COVID-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia 2021;186:289-98. https://doi.org/10.1007/s11046-021-00528-2
11. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post-coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol 2021;135:442-7. https://doi.org/10.1017/S0022215121000992
12. Kumar M, Sarma DK, Shubham S, Kumawat M, Verma V, Singh B, et al. Mucormycosis in COVID-19 pandemic: risk factors and linkages. Curr Res Microbiol Sci 2021;2:100057. https://doi.org/10.1016/j.jcrms.2021.100057
13. Bhargava D, Ahirwal R, Dubey S, Gurjar P, Pandey A, Beena S, et al. COVID induced functional exhaustion and persistently reduced lymphocytes as vital contributing factors for post-COVID rhino-orbital and cerebral mucormycosis in patients with diabetes: report from the Indian sub-continent. Head Neck Pathol 2021. https://doi.org/10.1007/s12105-021-01382-w [Epub ahead of print]
14. Al-Mahalawy H, El-Mahallawy Y, Dessoky NY, Ibrahim S, Amer H, Ayad HM, et al. Post-COVID-19 related osteonecrosis of the jaw (PC-RONJ): an alarming morbidity in COVID-19 surviving patients. BMC Infect Dis 2022;22:544. https://doi.org/10.1186/s12879-022-07518-9
15. Fakhruddin KS, Samaranayake LP, Buranawat B, Ngo H. Orofacial mucocutaneous manifestations of coronavirus disease-2019 (COVID-19): a systematic review. PLoS One 2022;17:e0265531. https://doi.org/10.1371/journal.pone.0265531
16. Gupta S, Saarikko M, Pütztner A, Räissänen IT, Sorsa T. Compromised periodontal status could increase mortality for patients with COVID-19. Lancet Infect Dis 2022;22:314. https://doi.org/10.1016/S1473-3099(22)00065-2
17. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolloso PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021;11:16144. https://doi.org/10.1038/s41598-021-95565-8
18. Mañón VA, Balandran S, Young S, Wong M, Melville JC. COVID-associated avascular necrosis of the maxilla-a rare, new side effect of COVID-19. J Oral Maxillofac Surg 2022. https://doi.org/10.1016/j.joms.2022.04.015 [Epub ahead of print]
19. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020;12:18. https://doi.org/10.1038/s41368-020-0074-x

How to cite this article: Park JY. Post-acute infection syndrome after COVID-19: effects on the oral and maxillofacial region and the recent publication trends. J Korean Assoc Oral Maxillofac Surg 2022;48:131-132. https://doi.org/10.5125/jkaoms.2022.48.3.131

Table 1. The manifestations of PAIS (post-acute infection syndrome) after COVID-19 presented in the oral and maxillofacial region

| Diagnosis                                                                 | The recent publications (reference No.) |
|--------------------------------------------------------------------------|----------------------------------------|
| Rhino-orbital-cerebral mucormycosis, COVID-19                            | 8-13                                   |
| Worsened periodontitis, ulceroo-necrotic gingivitis                      | 15,16                                  |
| Avascular osteomyelitis of maxilla                                       | 14,18                                  |
| Ulcerative oral mucosal lesions, petechiae, macules, blister, oral thrush with unknown etiology after COVID-19 | 15,19                                  |